KYNTRA BIO, INC. (KYNB): Nasdaq/NYSE listing notice — FibroGen receives Nasdaq notice of non-compliance for bid price below $1.00

KYNTRA BIO, INC.

Closing bid price of FGEN stock below $1.00 for 30 consecutive business days as of Oct 24, 2023.
Company has 180 calendar days (until April 22, 2024) to regain compliance.
To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days.
If not cured, FibroGen may qualify for an additional 180-day period if other listing standards met.
FibroGen states it meets all other Nasdaq continued listing requirements except bid price.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

KYNTRA BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

October 24, 2023, FibroGen, Inc. (“FibroGen”) received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying FibroGen that for the last 30 consecutive business days the bid price of FibroGen’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1). The notification received has no immediate effect on the listing of FibroGen’s common stock on Nasdaq. In accordance with listing rule 5810(c)(3)(A), FibroGen has 180 calendar days, or until April 22, 2024, to r

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-056018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.